Langlara (insulin glargine-aldy)
Biosimilar
- Region
- 🇺🇸 US
- Active substance
- insulin glargine-aldy
- Company
- Sunshine Lake Pharma Co Ltd
- Status
- Approved
- FDA approval
- Wed 29 Apr 2026
- Designations
- Biosimilar
- Application
- BLA761412
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Wed 29 Apr 2026🇺🇸 FDA approval
FDA approves biosimilar Langlara (insulin glargine-aldy)
Sunshine Lake Pharma Co Ltd; BLA761412; Biosimilar; injectable · source
Follow Langlara
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.